Mode
Text Size
Log in / Sign up
Phase 3 N=277 Randomized Single-blind Treatment

Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU1)

Sedation

Enrolled (actual)
277
Serious AEs
16.9%
Results posted
Mar 2026
Primary outcome: Primary: The Percentage of Time Sedation Depth is Maintained Within the Target Range, in Absence of Rescue Sedation, as Assessed According to the RASS Scale, in Isoflurane- vs Propofol-treated Patients — 70; 77.7 % of time of adequate sedation depth — p=<0.01

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Isoflurane (Drug); Propofol (Drug); Isoflurane (run-ins) (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Sedana Medical
Primary completion
Apr 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
The Percentage of Time Sedation Depth is Maintained Within the Target Range, in Absence of Rescue Sedation, as Assessed According to the RASS Scale, in Isoflurane- vs Propofol-treated Patients
70; 77.7 <0.01 sig
SECONDARY
Key Secondary: The Effect of Isoflurane vs Propofol on Use of Opioids During the Study Treatment Period
-0.26; -0.05 0.0470 sig
SECONDARY
Key Secondary: The Effect of Isoflurane vs Propofol on the Wake up Time at End of Study Drug Treatment
17; 27 0.229
SECONDARY
Key Secondary: The Effect of Isoflurane vs Propofol on Cognitive Recovery After End of Study Drug Treatment
19; 10; 9; 9; 7; 12 0.218
SECONDARY
Key Secondary: The Effect of Isoflurane vs Propofol on Spontaneous Breathing Effort During the Study Drug Treatment Period
58.9; 58 0.724
SECONDARY
Other Secondary: The Effect of Isoflurane vs Propofol on Time From Sedation Termination to Extubation in Patients for Whom Study Drug is Terminated for Extubation
109.5; 160 0.066
SECONDARY
Other Secondary: The Effect of Isoflurane vs Propofol on Days Alive and Free of Mechanical Ventilation Through Study Day 30
21.6; 19.7 0.174
SECONDARY
Other Secondary: The Effect of Isoflurane vs Propofol on Days Alive and Free of the ICU
15.4; 13.7 0.215
SECONDARY
Other Secondary: The Effect of Isoflurane vs Propofol on Delirium and Coma Free Days Until 7 Days After End of Study Treatment
2.5; 2.4 0.785
SECONDARY
Other Secondary: The Effect of Isoflurane vs Propofol on Mortality at 30 Days After Randomization
38; 22 0.219
SECONDARY
Other Secondary: The Effect of Isoflurane vs Propofol on Mortality at 3 Months After Randomization
53; 28 0.501
SECONDARY
Other Secondary: The Effect of Isoflurane vs Propofol on Mortality at 6 Months After Randomization
58; 31 0.415
SECONDARY
Other Secondary: Sedaconda ACD-S Device Deficiencies in Patients Receiving Isoflurane
1
SECONDARY
Other Secondary: The Use of Restraints in Patients Receiving Isoflurane vs Propofol
146; 74

Summary

This is a study to compare safety and efficacy of inhaled isoflurane administered via the Sedaconda ACD-S device system versus intravenous propofol for sedation of mechanically ventilated patients in the Intensive Care Unit (ICU) setting.

Eligibility Criteria

Inclusion Criteria

  • Adults ≥18 years of age;
  • Patients who are anticipated to require >12 hours of invasive mechanical ventilation and continuous sedation in the ICU; and
  • Receipt of continuous sedation due to clinical need for sedation to RASS 72 hours;
  • Severe neurological condition before ICU admission that causes the patient to lack ability to participate in the study (ie, unable to be assessed for RASS and CPOT);
  • Ventilator tidal volume 1000 mL at Baseline;
  • Need for extracorporeal membrane oxygenation (ECMO), extracorporeal CO2 removal (ECCO2R), high frequency oscillation ventilation (HFOV), or high frequency percussive ventilation (HFPV) at Screening;
  • Comfort care only (end of life care);
  • Contraindication to propofol or isoflurane;
  • Known or family history of MH;
  • Severe hemodynamic compromise, defined as the need for norepinephrine ≥0.3 mcg/kg/min (or equivalent vasopressor dose) to maintain blood pressure within acceptable range, assumed to be mean arterial pressure ≥65 mmHg unless prescribed clinically;
  • Allergy to isoflurane or propofol, or have propofol infusion syndrome.
  • History of ventricular tachycardia/Long QT Syndrome;
  • Requirement of IV benzodiazepine or barbiturate administration for seizures or dependencies, including alcohol withdrawal
  • Neuromuscular disease that impairs spontaneous ventilation (eg, C5 or higher spinal cord injury, amyotrophic lateral sclerosis, etc);
  • Concurrent enrollment in another study that, in the Investigator's opinion, would impact the patient's safety or assessments of this study;
  • Participation in other study involving investigational drug(s) or devices(s) within 30 days prior to Randomization;
  • Anticipated requirement of treatment with continuous infusion of a neuromuscular blocking agent for >4 hours;
  • Female patients who are pregnant or breast-feeding;
  • Imperative need for continuous active humidification through mechanical ventilation circuit;
  • Attending physician's refusal to include the patient; or
  • Inability to obtain informed consent.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05312385). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search